Ghaderi Bayazid, Moghbel Hamoon, Daneshkhah Nasrin, Babahajian Asrin, Sheikhesmaeili Farshad
Liver and digestive research center, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Instructor Paramedical Faculty, Kurdistan University of Medical Sciences, Sanandaj, Iran.
J Gastrointest Cancer. 2019 Sep;50(3):525-529. doi: 10.1007/s12029-018-0091-6.
ᅟ: Detection and quantitative measurements of diffused tumor markers in blood samples of patients with cancer is a facile and convenient method to determine prognosis and the appropriateness of the treatment. This study was done to evaluate the level of CA125, CEA, AFP, Beta HCG, and CA19-9 tumor markers and their relation to the stage and grade of the disease in patients with gastric adenocarcinoma.
In a descriptive cross-sectional study, of 81 patients referred to the oncology department of Tohid Hospital, Sanandaj, Iran, in 1 year, with recently detected gastric adenocarcinoma, serum level of CEA, CA19-9, CA125, AFP, and Beta HCG tumor markers was measured by ELISA method before chemotherapy and surgery. Patients were divided into four groups based on stage of disease (I, II, III, IV), and in terms of tumor differentiation, degrees were classified in to three groups: low, high, and intermediate. To determine the correlation of tumor markers level with the stage and grade of the disease, the Kruskal-Wallis and Mann-Whitney U tests were used.
By progression, the stages of the disease, the serum level of CA19-9, CA125, and AFP tumor markers demonstrated a significant increase. But this difference between level of HCG and CEA was not significant with the staging. There was no significant difference between the serum level of tumor markers and the grading of disease in the patients.
Preoperative CA19-9, CA125, and AFP tumor markers measurements could be beneficial in detecting the progressed stages of the disease.
检测和定量测量癌症患者血样中的扩散肿瘤标志物是一种简便易行的方法，可用于确定预后和治疗的适宜性。本研究旨在评估胃腺癌患者血清中CA125、CEA、AFP、β-HCG和CA19-9肿瘤标志物的水平及其与疾病分期和分级的关系。
在一项描述性横断面研究中，对伊朗萨南达季市托希德医院肿瘤科在1年内收治的81例近期确诊为胃腺癌的患者，在化疗和手术前采用酶联免疫吸附测定法（ELISA）测量血清中CEA、CA19-9、CA125、AFP和β-HCG肿瘤标志物的水平。根据疾病分期（I、II、III、IV期）将患者分为四组，并根据肿瘤分化程度分为低、高、中三组。为了确定肿瘤标志物水平与疾病分期和分级的相关性，采用了Kruskal-Wallis检验和Mann-Whitney U检验。
随着疾病进展，CA19-9、CA125和AFP肿瘤标志物的血清水平显著升高。但HCG和CEA水平在分期上无显著差异。患者肿瘤标志物血清水平与疾病分级之间无显著差异。
术前测量CA19-9、CA125和AFP肿瘤标志物有助于检测疾病的进展阶段。
